METXF (ME Therapeutics Holding) Shares Outstanding (EOP): 30.05 Mil (As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

METXF ME Therapeutics Holding Inc METXF
14 GF Score
Price $3.25
! 1 Warning Sign
View Full Analysis

What is ME Therapeutics Holding Shares Outstanding (EOP)?

ME Therapeutics Holding METXF 14 Shares Outstanding (EOP) is 30.05 Mil as of May. 2026. GuruFocus rates METXF with a GF Score™ of 14/100. The stock has 1 warning sign investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. ME Therapeutics Holding's shares outstanding for the quarter that ended in May. 2026 was 30.05 Mil.

ME Therapeutics Holding's quarterly shares outstanding stayed the same from Feb. 2026 (30.05 Mil) to May. 2026 (30.05 Mil).

ME Therapeutics Holding's annual shares outstanding increased from Aug. 2024 (25.19 Mil) to Aug. 2025 (29.59 Mil). It means ME Therapeutics Holding issued new shares from Aug. 2024 to Aug. 2025 .


ME Therapeutics Holding  (OTCPK:METXF) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


ME Therapeutics Holding Shares Outstanding (EOP) Related Terms


ME Therapeutics Holding Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for ME Therapeutics Holding's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ME Therapeutics Holding Shares Outstanding (EOP) Chart

ME Therapeutics Holding Annual Data
Trend Aug22 Aug23 Aug24 Aug25
Shares Outstanding (EOP)
23.56 23.56 25.19 29.59

ME Therapeutics Holding Quarterly Data
Aug22 Dec22 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 29.59 29.59 30.05 30.05 30.05

METXF vs VRTX, REGN, RVMD: Shares Outstanding (EOP) Comparison

For the Biotechnology subindustry, ME Therapeutics Holding's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ME Therapeutics Holding Shares Outstanding (EOP) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ME Therapeutics Holding's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where ME Therapeutics Holding's Shares Outstanding (EOP) falls into.


METXF
14GF Score
ME Therapeutics Holding Inc METXF
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ME Therapeutics Holding Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 30.05 Mil mean?
ME Therapeutics Holding (METXF) has a Shares Outstanding (EOP) of 30.05 Mil as of May. 2026. The total shares a company has outstanding, at period-end. View historical data on ME Therapeutics Holding and its competitors.
Is ME Therapeutics Holding's Shares Outstanding (EOP) too high?
ME Therapeutics Holding's current Shares Outstanding (EOP) is 30.05 Mil. Overall, ME Therapeutics Holding has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does ME Therapeutics Holding's Shares Outstanding (EOP) compare to VRTX and REGN?
ME Therapeutics Holding's Shares Outstanding (EOP) of 30.05 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Biotechnology company?
A good Shares Outstanding (EOP) depends on the Biotechnology industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on ME Therapeutics Holding and its competitors. ME Therapeutics Holding's current Shares Outstanding (EOP) is 30.05 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ME Therapeutics Holding stock overvalued right now?
ME Therapeutics Holding (METXF) has a current Shares Outstanding (EOP) of 30.05 Mil. The current Shares Outstanding (EOP) is 30.05 Mil. ME Therapeutics Holding's overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For ME Therapeutics Holding (METXF), the current Shares Outstanding (EOP) is 30.05 Mil as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ME Therapeutics Holding Business Description

Other Exchanges METX:Canada
Address 2665 East Mall, Room 249, Vancouver, BC, CAN, V6T 1Z4
ME Therapeutics Holding Inc is a preclinical stage biotechnology company working on cancer-fighting drugs in the field of Immuno Oncology, developing next-generation therapeutics targeting immune suppression in cancer. It is developing novel drugs that target myeloid cells to directly treat cancer and enhance the benefits of current Immuno Oncology drugs, such as checkpoint inhibitors in currently untreatable cancers. Immuno Oncology is a new area of cancer research that has been successful in treating previously untreatable cancers by targeting the immune system rather than the cancer directly, allowing a single drug to be used for multiple cancer types with mostly manageable side effects.
14GF Score

Get the complete analysis for METXF

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.25
Price